In conclusion, our results show that osteostatin downregulates the acute inflammatory response in gouty arthritis based on its favorable effect inhibiting caspase-1 and NF-κB activation, as well as promoting Nrf2 translocation, proving its potential interest as a new strategy for the development of future therapies in joint diseases. Here, CASP1 is linked to gout.